Tags : Engitix


Takeda Collaborates with Engitix to Target Fibrotic Liver Diseases

Shots: Engitix to receive up front with additional payments based on the confirmation and functional validation of selected targets and is eligible to receive $500M as preclinical, development, regulatory and commercial milestones along with royalties on sales of therapies Takeda to get the exclusive rights to develop and commercialize the candidate emerges from the collaboration. […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (December 09-13, 2019)

1.  Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders Published: Dec 12, 2019 | Tags: Pfizer, Amsparity, biosimilar, adalimumab, Receives, CHMP, Positive Opinion, Inflammatory, Autoimmune Disorders 2.  Janssen’s Darzalex (daratumumab) Combination Regimen Receives CHMP’s Positive Opinion for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma Published: Dec 13, 2019 | […]Read More


Engitix and Morphic Collaborate to Detect ECM-Related Targets in Fibrostenotic

Shots: The collaboration will deploy Engitix’s ECM platform to identify drug targets for potential future oral integrin drug therapies as treatments for fibrostenotic diseases The ECM platform will be used to characterize the expression of drug therapies and cover integrin/ non-integrin expression in fibrostenosis. Morphic will advance therapies for patients with autoimmune, CV, metabolic diseases, […]Read More